Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2013 1
2014 1
2015 1
2016 2
2017 2
2018 1
2019 4
2020 8
2021 3
2022 1
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.
Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ, Huang R, Jiang L, Choe S, Fan B, Yen K, Lu M, Bowden C, Steelman L, Pandya SS, Cloughesy TF, Wen PY. Mellinghoff IK, et al. Among authors: de la fuente mi. J Clin Oncol. 2020 Oct 10;38(29):3398-3406. doi: 10.1200/JCO.19.03327. Epub 2020 Jun 12. J Clin Oncol. 2020. PMID: 32530764 Free PMC article. Clinical Trial.
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. Brastianos PK, et al. Among authors: de la fuente mi. N Engl J Med. 2023 Jul 13;389(2):118-126. doi: 10.1056/NEJMoa2213329. N Engl J Med. 2023. PMID: 37437144 Free PMC article. Clinical Trial.
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA 3rd, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, Chun S, Young RJ, Liu H, Choe S, Lu M, Le K, Hassan I, Steelman L, Pandya SS, Cloughesy TF, Wen PY. Mellinghoff IK, et al. Among authors: de la fuente mi. Clin Cancer Res. 2021 Aug 15;27(16):4491-4499. doi: 10.1158/1078-0432.CCR-21-0611. Epub 2021 Jun 2. Clin Cancer Res. 2021. PMID: 34078652 Free PMC article. Clinical Trial.
Adult-type Diffuse Gliomas.
de la Fuente MI. de la Fuente MI. Continuum (Minneap Minn). 2023 Dec 1;29(6):1662-1679. doi: 10.1212/CON.0000000000001352. Continuum (Minneap Minn). 2023. PMID: 38085893
Therapies for IDH-Mutant Gliomas.
Alshiekh Nasany R, de la Fuente MI. Alshiekh Nasany R, et al. Curr Neurol Neurosci Rep. 2023 May;23(5):225-233. doi: 10.1007/s11910-023-01265-3. Epub 2023 Apr 15. Curr Neurol Neurosci Rep. 2023. PMID: 37060388 Free PMC article. Review.
Targeting IDH1/IDH2 mutations in gliomas.
de la Fuente MI. de la Fuente MI. Curr Opin Neurol. 2022 Dec 1;35(6):787-793. doi: 10.1097/WCO.0000000000001111. Epub 2022 Oct 21. Curr Opin Neurol. 2022. PMID: 36367045 Review.
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V. de la Fuente MI, et al. Neuro Oncol. 2023 Jan 5;25(1):146-156. doi: 10.1093/neuonc/noac139. Neuro Oncol. 2023. PMID: 35639513 Free PMC article. Clinical Trial.
The role of bevacizumab in the treatment of glioblastoma.
Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ. Diaz RJ, et al. Among authors: de la fuente mi. J Neurooncol. 2017 Jul;133(3):455-467. doi: 10.1007/s11060-017-2477-x. Epub 2017 May 19. J Neurooncol. 2017. PMID: 28527008 Review.
28 results